DashboardPortfoliosWatchlistCommunityDiscoverScreener
  • Community
  • /
  • United Kingdom
  • /
  • Healthcare
Author Program NEWCreate Narrative
CTEC logo

Convatec Group PLC Stock Price

LSE:CTEC Community·UK£4.3b Market Cap
  • 1 Narratives written by author
  • 0 Comments on narratives written by author
  • 24 Fair Values set on narratives written by author
Author Program NEWCreate Narrative

CTEC Share Price Performance

UK£2.21
-0.15 (-6.36%)
​
UK£3.02
Fair Value
UK£2.21
-0.15 (-6.36%)
26.9% undervalued intrinsic discount
UK£3.02
Fair Value
Price UK£2.21
AnalystConsensusTarget UK£3.02
Mon, 22 Jun 26
Fair ValueUK£3.02
Share Pricen/a

CTEC Community Narratives

AN
AnalystConsensusTarget
AnalystConsensusTarget's
Fair Value
·
Fair Value UK£3.02 26.9% undervalued intrinsic discount

Global Demographic Shifts And Emerging Markets Will Create Enduring Opportunity

0users have liked this narrative
0users have commented on this narrative
19users have followed this narrative
CTEC logo
Convatec Group
26.9% undervalued intrinsic discount

Global Demographic Shifts And Emerging Markets Will Create Enduring Opportunity

View narrative
AN
AnalystConsensusTarget
AnalystConsensusTarget
Updated 22 Jun
Read Narrative

Trending Discussion

No trending discussion available.

Recently Updated Narratives

AN
AnalystConsensusTarget
CTEC logo

CTEC: Advanced Wound Care Pipeline Will Support Future Rerating Potential

Fair Value: UK£3.02 26.9% undervalued intrinsic discount
19 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative

Snowflake Analysis

High growth potential with slight risk.

4 Risks
3 Rewards
View Full Analysis

Convatec Group PLC Key Details

US$2.5b

Revenue

US$1.1b

Cost of Revenue

US$1.4b

Gross Profit

US$1.3b

Other Expenses

US$124.0m

Earnings

Last Reported Earnings
Jun 30, 2026
Next Reporting Earnings
Feb 23, 2027
0.063
56.00%
4.98%
113.8%
View Full Analysis

About CTEC

Founded
1978
Employees
10000
CEO
Jonathan Mason
WebsiteView website
www.convatecgroup.com

Convatec Group PLC engages in the development, manufacturing, and sale of medical products, services and technologies for the management of chronic conditions in Europe, North America, and internationally. The company offers advanced wound care products for the management of acute and chronic wounds resulting from various conditions, such as diabetes, and acute conditions resulting from traumatic injury and burns. It also provides ostomy care solutions, including devices, accessories, and services for people with a stoma resulting from colorectal cancer, bladder cancer, inflammatory bowel disease, and trauma. In addition, the company offers continence care products and services for people with urinary continence issues related to spinal cord injuries, neurological disease, prostate enlargement or other causes. Further, it provides infusion care solutions comprising disposable infusion sets for diabetes insulin pumps, or for use in continuous infusion treatments for conditions such as Parkinson’s disease. The company sells its products to pharmacies, hospitals, and other acute and post-acute healthcare service providers directly or through distributors and wholesalers. It serves a range of customers, including healthcare providers, patients, and manufacturers. Convatec Group PLC was founded in 1978 and is headquartered in London, the United Kingdom.

Recent CTEC News & Updates

Recent updates

No updates

Convatec Group PLC Competitors

SN. logo

Smith & Nephew

Symbol: LSE:SN.
Market cap: UK£8.6b
SPI logo

Spire Healthcare Group

Symbol: LSE:SPI
Market cap: UK£985.5m
CVSG logo

CVS Group

Symbol: LSE:CVSG
Market cap: UK£876.8m
View more competitors

Make Better Investing Decisions Anywhere

Scan to download
Open AppStoreOpen Google Play
Chrome Web Store
Level 5, 320 Pitt Street, Sydney
Financial Data provided by S&P Global Market Intelligence LLC, analysis provided by Simply Wall Street Pty Ltd. Copyright © 2026, S&P Global Market Intelligence LLC. All rights reserved.
View Data Sources
Markets
  • US: NYSE & NASDAQ
  • UK: FTSE
  • Australia: ASX
  • India: NIFTY
  • Canada: TSX
  • South Africa: JSE
  • Japan: NIKKEI
  • South Korea: KOSPI
  • Germany: DAX
Investing Ideas
  • Undervalued Companies
  • Dividend Powerhouses
  • Insider Buying
  • Nuclear Energy
  • Autonomous Vehicles
  • Artificial Intelligence
  • Crypto and Blockchain
  • Cybersecurity
  • More ideas
Stock Communities
  • AstraZeneca
  • HSBC Holdings
  • Shell
  • Unilever
  • Diageo
  • Rio Tinto Group
  • RELX
  • BP
  • Barclays
Features & Tools
  • Portfolio Tracker
  • Stock Screener & Alerts
  • Narratives & Fair Values
  • Dividend Calculator
News & Discovery
  • Latest Stock News
  • Global Market Insights
  • The Foxhole
  • Investing Ideas
  • Community Narratives
  • What's New
Simply Wall St
  • Plans & Pricing
  • Advertising
  • About Us
  • Contact Us
  • Careers
  • Help Center
  • Learn Stock Investing
  • Affiliate Program
  • Business & Enterprise
  • Charlie AI
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
© 2026 Simply Wall Street Pty Ltd, US Design Patent #29/544/281, Community and European Design Registration #2845206
  • Terms and Conditions
  • Privacy Policy
  • AI Terms
  • Financial Services Guide